SCHEMBL3568701

SCHEMBL3568701

Cc1cccc(CNc2c(C#N)cnc3oc(-c4ccccc4)c(-c4ccccc4)c23)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 5/20 0.42
KDM4E B2RXH2 5/20 0.42
CYP3A4 P08684 4/20 0.42
CYP2D6 P10635 3/20 0.42
CYP2C19 P33261 3/20 0.42
RXFP1 Q9HBX9 2/20 0.42
KDR P35968 2/20 0.42
AURKA O14965 5/20 0.42
TSHR P16473 4/20 0.42
HSD17B10 Q99714 4/20 0.42
HPGD P15428 3/20 0.42
ALDH1A1 P00352 3/20 0.42
TP53 P04637 3/20 0.42
CYP2C9 P11712 3/20 0.42
MAPK1 P28482 2/20 0.41
MAPT P10636 1/20 0.41
LMNA P02545 2/20 0.41
USP2 O75604 1/20 0.41
ALOX15 P16050 1/20 0.41
CLK4 Q9HAZ1 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3568846 0.77 TNK2 (0.50) KDRAURKATNK2KMT2AMEN1
SCHEMBL3563328 0.77 AURKA (0.51) KDM4EAURKATSHRHSD17B10HPGD
SCHEMBL3564842 0.77 AURKA (0.48) KDRAURKATNK2CHEK1MAP2K1
SCHEMBL3566457 0.76 LRRK2 (0.49) KDM4EKDRAURKAHSD17B10HPGD
SCHEMBL3576476 0.76 KMT2A (0.58) KDM4EAURKATSHRHSD17B10HPGD
SCHEMBL13462029 0.75 TNK2 (0.48) KDM4ERXFP1KDRAURKATSHR
SCHEMBL3562107 0.74 AURKA (0.62) CYP1A2KDM4EKDRAURKAHSD17B10
SCHEMBL3579856 0.74 CHEK1 (0.47) KDM4EAURKATSHRHSD17B10HPGD
SCHEMBL3561696 0.74 TNK2 (0.64) KDM4EKDRHPGDALDH1A1TNK2
SCHEMBL3566479 0.74 KDM4E (0.53) KDM4EKDRAURKATSHRHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7674907-B2 Furanopyridine derivatives and methods of use AMGEN INC. (US) 2010-03-09 US claimed
US-20060046977-A1 Furanopyridine derivatives and methods of use AMGEN INC. 2006-03-02 US claimed
US-7674907-B2 Furanopyridine derivatives and methods of use AMGEN INC. (US) 2010-03-09 US disclosed
EP-1791845-A2 FURANOPYRIDINE DERIVATIVES AS ACK1 AND LCK MODULATORS AMGEN INC. (US) 2007-06-06 EP disclosed
WO-2006130160-A2 FURANOPYRIDINE DERIVATIVES AS ACK1 AND LCK MODULATORS AMGEN INC. (US) 2006-12-07 WO disclosed
US-20060046977-A1 Furanopyridine derivatives and methods of use AMGEN INC. 2006-03-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060046977-A1 Furanopyridine derivatives and methods of use LCK, NFATC1, MINK1 CYP1A2 1386/4885KDM4E 2251/4885CYP3A4 1135/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.